Salubris Pharmaceuticals (002294.SZ) plans to repurchase a 6.14% equity stake in its subsidiary Xintai Medical for RMB 427 million.

Zhito Finance APP News: Salubris (002294.SZ) announced that recently, in accordance with the repurchase clauses stipulated in the original agreement, given that Salubris Medical failed to achieve a qualified initial public offering within the agreed timeframe, the company intends to fulfill its equity repurchase obligation as agreed and sign a Transfer Agreement with the investors. The company will, as agreed, use self-raised funds of RMB 427 million to repurchase a total of 6.1424% equity in Salubris Medical held by the investors. After the repurchase is completed, the company's shareholding in Salubris Medical will increase from 87.3639% to 93.5063%.